1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
| Ticker |
Sentiment |
Impact |
|
APLS
|
Somewhat Bullish
|
29 %
|
|
BAC
|
Neutral
|
12 %
|
|
ALPMF
|
Neutral
|
6 %
|
